Adial Pharmaceuticals(ADIL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADIL Adial Pharmaceuticals

休市中 08-21 16:00:00 EDT

6.22

+0.32

+5.34%

盘后6.03

-0.18-2.98%

19:30 EDT

最高6.41	最低5.74	成交量8.20万
今开5.95	昨收5.90	日振幅11.36%
总市值1,632万	流通市值1,582万	总股本262.59万
成交额49.40万	换手率3.22%	流通股本254.53万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADIL","market":"US","secType":"STK","nameCN":"Adial Pharmaceuticals","latestPrice":6.215,"timestamp":1787342400000,"preClose":5.9,"halted":0,"volume":81991,"hourTrading":{"tag":"盘后","latestPrice":6.03,"preClose":6.215,"latestTime":"19:30 EDT","volume":947,"amount":5743.762,"timestamp":1787355044282,"change":-0.185,"changeRate":-0.029767,"amplitude":0.034594},"delay":0,"changeRate":0.05338983050847449,"floatShares":2545297,"shares":2625899,"eps":-17.71,"marketStatus":"休市中","change":0.315,"latestTime":"08-21 16:00:00 EDT","open":5.95,"high":6.41,"low":5.74,"amount":493984.542233,"amplitude":0.113559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-17.71,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532664000000,"exchange":"NASDAQ","adjPreClose":5.9,"preHourTrading":{"tag":"盘前","latestPrice":5.89,"preClose":5.9,"latestTime":"09:29 EDT","volume":1660,"amount":9854.74687,"timestamp":1787318999999,"change":-0.01,"changeRate":-0.001695,"amplitude":0.044915},"postHourTrading":{"tag":"盘后","latestPrice":6.03,"preClose":6.215,"latestTime":"19:30 EDT","volume":947,"amount":5743.762,"timestamp":1787355044282,"change":-0.185,"changeRate":-0.029767,"amplitude":0.034594},"volumeRatio":0.9180844418930033,"impliedVol":1.6275,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADIL/wiki","defaultTab":"wiki","newsList":[{"id":"1189512135","title":"Adial Pharmaceuticals 预计股东批准后将迎来董事会变动及资深成员辞职——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1189512135","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189512135?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:32","pubTimestamp":1786656775,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的文件，Adial Pharmaceuticals 预计在股东批准后，将迎来董事会重组，并面临多位资深成员辞职的局面。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160647120","title":"Adial Pharmaceuticals披露：首席财务官Vinay Shah将在2026年股东大会后离任","url":"https://stock-news.laohu8.com/highlight/detail?id=1160647120","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160647120?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:29","pubTimestamp":1786656553,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals日前通过美国证券交易委员会（SEC）提交的文件透露，公司预计将在2026年年度股东大会之后，终止首席财务官Vinay Shah的职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124418940","title":"Alliance Global Partners首次覆盖Adial Pharmaceuticals，给予买入评级，目标价11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124418940","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124418940?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:09","pubTimestamp":1785755349,"startTime":"0","endTime":"0","summary":"盟全球伙伴（Alliance Global Partners）正式启动对Adial Pharmaceuticals的覆盖研究，并给予其“买入”评级。这家投行为该股设定的目标价格高达每股11美元。这一动作，无疑为市场注入了新的关注焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133772257","title":"海岸地资本申报被动持股Adial Pharmaceuticals达9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133772257","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133772257?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:38","pubTimestamp":1782311894,"startTime":"0","endTime":"0","summary":"根据一份提交至美国证券交易委员会（SEC）的文件披露，截至6月17日，海岸地资本有限合伙公司（Coastlands Capital Lp）持有Adial Pharmaceuticals公司9.98%的股份。该持仓被申报为被动投资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123009586","title":"交易后股权结构：Adial原股东持股7.7%，Azora持股51%，投资方持普通股41.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123009586","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123009586?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:45","pubTimestamp":1781192722,"startTime":"0","endTime":"0","summary":"根据最新披露的股权安排，在完成相关交易后，Adial Pharmaceuticals的普通股持股比例已明确划分。原Adial股东将保留7.7%的股权，Azora方面将持有51%的股份，而其他投资方则共同拥有剩余41.3%的普通股份额。这一股权结构标志着公司资本层面的重大调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128848028","title":"Adial制药向FDA局长国家优先凭证试点项目提交Ad04临床开发计划申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1128848028","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128848028?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:50","pubTimestamp":1777294213,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals已正式向美国食品药品监督管理局（FDA）局长国家优先凭证（CNPV）试点项目提交申请，旨在推动其核心候选药物Ad04的临床开发计划。\n这一战略性举措标志着公司在推进治疗酒精使用障碍创新疗法方面迈出关键一步。若申请获批，将有望加速Ad04的临床开发进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189551719","title":"Adial制药成功完成示范批次生产，为Ad04计划三期试验铺平临床与注册生产道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1189551719","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189551719?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:36","pubTimestamp":1776864984,"startTime":"0","endTime":"0","summary":"Adial制药近日宣布已顺利完成示范批次的生产工作，这一关键进展为其候选药物Ad04计划中的三期临床试验扫清了障碍。此次成功生产不仅验证了工艺流程的稳定性，更意味着公司已具备开展临床用药和注册申报所需药品的规模化生产能力。该里程碑事件为Ad04后续的临床推进奠定了坚实基础，标志着公司向实现该疗法商业化目标迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197605534","title":"Adial Pharmaceuticals与Molteni Farmaceutici签署欧洲独家Ad04合作框架，潜在特许权使用费及里程碑款项近6000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197605534","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197605534?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:22","pubTimestamp":1772544162,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals宣布与意大利制药企业Molteni Farmaceutici达成欧洲地区独家合作框架协议，共同推进酒精使用障碍治疗药物Ad04的研发与商业化。根据协议条款，若双方后续签署正式合作协议，Adial有望获得近6000万美元的潜在特许权使用费及里程碑款项。此次合作将结合Molteni在欧洲市场的深厚渠道资源与Adial的专有技术，加速该疗法惠及目标患者群体。业内人士指出，此类跨国合作不仅为生物科技公司提供了关键的资金与资源支持，亦凸显了欧洲市场对创新成瘾治疗方案的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196307056","title":"Adial制药公司：近期将启动关键性三期临床试验项目，正与潜在美国商业伙伴接洽","url":"https://stock-news.laohu8.com/highlight/detail?id=1196307056","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196307056?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:19","pubTimestamp":1772543952,"startTime":"0","endTime":"0","summary":"Adial制药公司宣布，公司计划在近期启动其关键性三期临床试验项目，目前正积极与美国市场的潜在商业合作伙伴进行接洽。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614302848","title":"Adial Pharmaceuticals, Inc盘中异动 早盘大幅拉升6.64%报2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614302848","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614302848?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:40","pubTimestamp":1772116801,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日22时40分，Adial Pharmaceuticals, Inc股票出现异动，股价急速拉升6.64%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体跌幅为1.23%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。该公司开发用于治疗成瘾和相关疾病的处方药，其主导产品是AD04，用于治疗饮酒障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226224001a722e24b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226224001a722e24b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518276929","title":"Adial Pharmaceuticals, Inc盘中异动 股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518276929?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:51","pubTimestamp":1741618263,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时51分，Adial Pharmaceuticals, Inc股票出现异动，股价大幅跳水5.32%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Protagonist Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3497.85%、773.50%、700.91%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.34%、41.36%、40.33%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225103abf31a33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225103abf31a33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517898710","title":"Adial Pharmaceuticals(ADIL.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.15美元，前值为-0.37美元，预期值为-0.33美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517898710","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517898710?lang=zh_cn&edition=full","pubTime":"2025-03-05 06:45","pubTimestamp":1741128356,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals(ADIL.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.15美元，前值为-0.37美元，预期值为-0.33美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05064548524579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184810783","title":"Adial Pharmaceuticals FY 2024 GAAP每股收益$(2.72) 超出预期$(2.97)","url":"https://stock-news.laohu8.com/highlight/detail?id=1184810783","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184810783?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:01","pubTimestamp":1741100473,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals报告季度每股亏损$，超出分析师共识预期的$，超出预期8.42％。这相比去年同期每股亏损$，是24.44％的增长。以上内容来自Benzinga Earnings专栏，原文如下：$Adial Pharmaceuticals$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 8.42 percent. This is a 24.44 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adial Pharmaceuticals FY 2024 GAAP每股收益$(2.72) 超出预期$(2.97)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634693","title":"Adial Pharmaceuticals, Inc盘中异动 快速下挫7.01%报0.730美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634693","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634693?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012280,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Adial Pharmaceuticals, Inc股票出现波动，股价急速下跌7.01%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Allarity Therapeutics, Inc.、Aeon Biopharma, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为46.98%、22.45%、21.90%，振幅较大的相关个股有Galmed Pharmaceuticals Ltd.、Adial Pharmaceuticals, Inc、Akari Therapeutics Plc，振幅分别为9.35%、7.01%、6.78%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223120a25d3f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223120a25d3f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514383707","title":"Adial Pharmaceuticals, Inc盘中异动 早盘急速下跌5.18%报0.791美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514383707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514383707?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:37","pubTimestamp":1740667061,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时37分，Adial Pharmaceuticals, Inc股票出现异动，股价大幅跳水5.18%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体涨幅为0.85%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。该公司开发用于治疗成瘾和相关疾病的处方药，其主导产品是AD04，用于治疗饮酒障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223741a2567bb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223741a2567bb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856843","title":"Adial Pharmaceuticals, Inc盘中异动 大幅跳水12.23%报0.810美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856843?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:33","pubTimestamp":1740580382,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时33分，Adial Pharmaceuticals, Inc股票出现异动，股价快速跳水12.23%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Nutriband Inc C/Wts 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2950.93%、121.39%、91.44%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为78.81%、16.86%、14.35%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223302a254f6e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223302a254f6e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513072706","title":"Adial Pharmaceuticals, Inc盘中异动 早盘股价大跌5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513072706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513072706?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:40","pubTimestamp":1740408057,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时40分，Adial Pharmaceuticals, Inc股票出现异动，股价大幅跳水5.98%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为67.01%、49.72%、24.56%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Vaxart, Inc. - Common Stock，振幅分别为92.70%、27.99%、21.42%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224224058abdb102a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224224058abdb102a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512316610","title":"Adial Pharmaceuticals, Inc盘中异动 急速拉升5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512316610","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512316610?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:47","pubTimestamp":1739890070,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时47分，Adial Pharmaceuticals, Inc股票出现波动，股价大幅上涨5.23%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体涨幅为0.92%。其相关个股中，Solid Biosciences Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为310.07%、118.66%、90.14%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.，振幅分别为41.79%、34.04%、26.83%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822475096279ade&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822475096279ade&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510135151","title":"Adial Pharmaceuticals, Inc盘中异动 急速下跌6.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510135151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510135151?lang=zh_cn&edition=full","pubTime":"2025-02-12 04:12","pubTimestamp":1739304758,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日04时12分，Adial Pharmaceuticals, Inc股票出现波动，股价大幅跳水6.23%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Omega Therapeutics, Inc.、Dermata Therapeutics Inc C/Wts 、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3206.83%、1502.15%、512.74%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、72.23%、64.94%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212041239a2424291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212041239a2424291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508463211","title":"Adial Pharmaceuticals, Inc盘中异动 股价大跌5.89%报0.780美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508463211","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508463211?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:35","pubTimestamp":1738683327,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时35分，Adial Pharmaceuticals, Inc股票出现异动，股价快速下挫5.89%。Adial Pharmaceuticals, Inc股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为1515.48%、888.69%、224.86%，振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Viracta Therapeutics, Inc.，振幅分别为64.17%、49.88%、44.22%。Adial Pharmaceuticals, Inc公司简介：Adial Pharmaceuticals Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204233527a2393591&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204233527a2393591&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adialpharma.com","stockEarnings":[{"period":"1week","weight":0.5616},{"period":"1month","weight":1.3019},{"period":"3month","weight":1.988},{"period":"6month","weight":1.5367},{"period":"1year","weight":-0.3319},{"period":"ytd","weight":0.13}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Adial Pharmaceuticals, Inc.于2010年11月成立为弗吉尼亚有限责任公司。该公司是一家临床阶段的生物制药公司，专注于开发治疗或预防成瘾和相关疾病的疗法。该公司的研究性新药候选药物AD04正在开发中，作为一种治疗剂，用于治疗酒精使用障碍（“AUD”）。AD04最近在一项3期临床试验中进行了研究，指定为ONWARD试验，用于对具有某些目标基因型的受试者进行AUD的潜在治疗，这些目标基因型是使用伴随诊断基因测试确定的。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.058856},{"month":2,"riseRate":0.25,"avgChangeRate":-0.031808},{"month":3,"riseRate":0,"avgChangeRate":-0.155549},{"month":4,"riseRate":0.375,"avgChangeRate":-0.03424},{"month":5,"riseRate":0.375,"avgChangeRate":-0.002623},{"month":6,"riseRate":0.375,"avgChangeRate":-0.130351},{"month":7,"riseRate":0.625,"avgChangeRate":0.108193},{"month":8,"riseRate":0.222222,"avgChangeRate":0.030246},{"month":9,"riseRate":0.375,"avgChangeRate":-0.037962},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152838},{"month":11,"riseRate":0.375,"avgChangeRate":0.139286},{"month":12,"riseRate":0.375,"avgChangeRate":0.00671}],"exchange":"NASDAQ","name":"Adial Pharmaceuticals","nameEN":"Adial Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adial Pharmaceuticals(ADIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Adial Pharmaceuticals(ADIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Adial Pharmaceuticals,ADIL,Adial Pharmaceuticals股票,Adial Pharmaceuticals股票老虎,Adial Pharmaceuticals股票老虎国际,Adial Pharmaceuticals行情,Adial Pharmaceuticals股票行情,Adial Pharmaceuticals股价,Adial Pharmaceuticals股市,Adial Pharmaceuticals股票价格,Adial Pharmaceuticals股票交易,Adial Pharmaceuticals股票购买,Adial Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adial Pharmaceuticals(ADIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Adial Pharmaceuticals(ADIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}